Optic Neuropathy, Ischemic
6
1
1
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
33%
2 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Building Research With Artificial Intelligence in Neuro-Ophthalmology
Optic Nerve Sheath Ultrasound in Giant Cell Arteritis
Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%
Retrobulbar Triamcinolone Acetonide Injection in the Treatment of NA-AION